Document Detail

Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients--a pharmacoeconomic analysis.
MedLine Citation:
PMID:  20699258     Owner:  NLM     Status:  In-Data-Review    
Background: Prevention of in-hospital venous thromboembolism (VTE) is identified internationally as a priority to improve patient safety. Advocated alternatives include low-dose unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH). Although LMWHs are as effective as UFH, less frequent administration and potentially safer adverse effect profile associated with LMWHs might off-set greater drug acquisition costs. The objective of this study was to determine the most cost-effective thromboprophylaxis strategy for hospitalized medicine patients and specific subgroups in Canada. Methods: A decision-analytic model assessed costs and outcomes of LMWH compared to UFH for thromboprophylaxis in at-risk hospitalized medicine patients from an institutional perspective. The outcome of interest was the incremental cost-effectiveness ratio (ICER) for preventing deep vein thrombosis (DVT) and combined untoward events (pulmonary embolism [PE], major bleed, and death). The time horizon of the model was the hospital stay. Results: In the base-case analysis, LMWH thromboprophylaxis resulted in higher costs ($7.40), but 3.6 and 1.1 fewer DVT and untoward events per 1000 patients, respectively, with associated ICERs of $2042 and $6832. Results remained predominantly stable when alternative assumptions were evaluated in the sensitivity analysis. Low-molecular-weight heparin had the most favorable economic profile in patients with a history of DVT. In the probabilistic sensitivity analysis, in 33% of simulations LMWH was less costly and more effective, whereas the reverse was true for UFH only in 13% of simulations. Conclusions: Low-molecular-weight heparin administration is a cost-effective alternative for thromboprophylaxis strategy in Canadian hospitalized medicine patients.
Kerry Wilbur; L D Lynd; M Sadatsafavi
Related Documents :
19891208 - The association of willingness-to-pay and patient attributes: a cost-volume-profit anal...
11852378 - Management of diabetic foot lesions in hospital: costs and benefits.
12097178 - An economic evaluation of the highlands and islands teledentistry project.
23335298 - Safety risks in the ambulatory setting.
22736748 - Increased hospitalizations and death in patients with esrd secondary to lupus.
18360048 - Clinical efficacy of a new angiotensin ii type 1 receptor blocker, pratosartan, in hype...
Publication Detail:
Type:  Journal Article     Date:  2010-08-10
Journal Detail:
Title:  Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis     Volume:  17     ISSN:  1938-2723     ISO Abbreviation:  Clin. Appl. Thromb. Hemost.     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-09-29     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9508125     Medline TA:  Clin Appl Thromb Hemost     Country:  United States    
Other Details:
Languages:  eng     Pagination:  454-65     Citation Subset:  IM    
1College of Pharmacy, Qatar University, Doha, Qatar.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Venous gangrene a rare but dreadful complication of deep venous thrombosis.
Next Document:  Effects of Pegylated Interferon {alpha} on Fibrinolytic Parameters in Patients With Chronic Hepatiti...